Mercaptopurine NDC 0054-0879

NDC codes

FDA NDC Directory

Product NDC (as listed)0054-0879Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00054-0879Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0054-0879-49	00054087949	1 BOTTLE, GLASS in 1 CARTON (0054-0879-49) / 100 mL in 1 BOTTLE, GLASSMarketed from Jun 16, 2025

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mercaptopurine
Generic name (nonproprietary): mercaptopurine
Active ingredients: Mercaptopurine — 20 mg/mL
Dosage form: Suspension
Route: Oral
Labeler: Hikma Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216418
Marketing start: Jun 16, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 0054-0879_7490a828-2b59-4972-9a51-fe5173e81aecSPL ID 7490a828-2b59-4972-9a51-fe5173e81aecSPL set ID 0a366cf3-91f0-4aa4-8f34-a7a27cad8f15RxCUI 1536484UNII E7WED276I5
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400054087949 followed by a unit qualifier and the quantity

Package 00054-0879-49. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 22, 2026.

Indications (excerpt from the label)

Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. ( 1.1 ) 1.1 Acute Lymphoblastic Leukemia Mercaptopurine is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216418

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216418
Product	Strength	Form · route	Labeler	Product NDC
Mercaptopurine	Mercaptopurine 20 mg/mL	SuspensionOral	Hikma Pharmaceuticals USA Inc.	0054-4582